From 21 to 28 November 2014, nearly 700 organisations across Europe will host activities to increase awareness of the personal and public health benefits of HIV testing. As HIV infection can remain asymptomatic for a long time and a substantial number of infected persons across Europe are unaware of their infection, ECDC supports the aims of this second European HIV testing week.
This report summarises the surveillance results for Neisseria gonorrhoeae antimicrobial susceptibility in the EU/EEA. In 2012, 20 EU/EEA Member States participated in Euro-GASP.
Monitoring and responding to HIV and hepatitis C among people who inject drugs is the focus of two new reports from the EU drugs agencies EMCDDA and ECDC.
This survey was designed to collect information on the laboratory diagnosis of gonorrhoea, chlamydia and syphilis; clinical reporting; laboratory capacity for testing; laboratory accreditation and external quality assessment (EQA); training; reporting and laboratory systems.
This report presents the results from the 2011 gonococcal antimicrobial susceptibility surveillance programme (Euro-GASP) and a summary of the second distribution from the 2011 external quality assurance (EQA) scheme.
In 2011, a pilot study was undertaken to assess the public health benefit of molecular surveillance for gonorrhoea in 21 EU/EEA countries. A total of 1 066 isolates collected under the 2010 European gonococcal antimicrobial surveillance programme were typed and 406 sequence types identified, with considerable diversity among countries.
In 2010, 21 EU/EEA Member States participated in the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), testing a total of 1766 isolates.